Jacobs & Co. CA Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Jacobs & Co. CA reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 9,521 shares of the biopharmaceutical company’s stock after selling 161 shares during the quarter. Jacobs & Co. CA’s holdings in Regeneron Pharmaceuticals were worth $8,362,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of REGN. Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $697,296,000. FMR LLC grew its position in shares of Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after acquiring an additional 669,517 shares in the last quarter. Moneta Group Investment Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 57,848.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 582,384 shares of the biopharmaceutical company’s stock worth $420,184,000 after purchasing an additional 581,379 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Regeneron Pharmaceuticals by 129.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock worth $190,170,000 after purchasing an additional 122,103 shares during the period. Finally, Virginia Retirement Systems ET AL bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $83,318,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,707 shares of the company’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the transaction, the director now owns 6,382 shares in the company, valued at approximately $6,062,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Joseph L. Goldstein sold 2,707 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the transaction, the director now owns 6,382 shares in the company, valued at $6,062,900. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,729 shares of company stock worth $13,124,641. Insiders own 8.83% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on REGN shares. Truist Financial reiterated a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday. BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the company an “outperform” rating in a research note on Wednesday, December 6th. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the stock a “neutral” rating in a report on Tuesday, February 6th. Finally, Royal Bank of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $1,096.00 to $1,184.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $967.59.

Regeneron Pharmaceuticals Trading Up 0.3 %

Shares of REGN stock opened at $966.30 on Thursday. The stock has a market capitalization of $106.06 billion, a PE ratio of 27.81, a P/E/G ratio of 2.77 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The business has a 50-day moving average of $957.54 and a 200 day moving average of $878.93. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter last year, the firm posted $10.96 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.75 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.